牛牛AI助手已提取核心信息
Altamira Therapeutics Ltd., a Bermuda-incorporated company, has successfully completed the partial spin-off of its Bentrio business, selling a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as reported on January 19, 2024. The transaction, which closed on November 21, 2023, is part of Altamira's strategic repositioning to focus on its RNA delivery technology. The company received approximately $2.3 million in cash for the majority stake and retained a 49% interest in Medica. Additionally, Altamira is entitled to 25% of Medica's future gross licensing income. The deal also included the sale of Auris Medical Pty Ltd and a cash contribution to Medica's capital. Altamira anticipates a financial gain of about $5.2 million from the transaction, which will be recorded in accordance with International Financial Reporting Standards. The unaudited pro forma financial information reflecting the transaction has been filed with the U.S. Securities and Exchange Commission.
Altamira Therapeutics Ltd., a Bermuda-incorporated company, has successfully completed the partial spin-off of its Bentrio business, selling a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as reported on January 19, 2024. The transaction, which closed on November 21, 2023, is part of Altamira's strategic repositioning to focus on its RNA delivery technology. The company received approximately $2.3 million in cash for the majority stake and retained a 49% interest in Medica. Additionally, Altamira is entitled to 25% of Medica's future gross licensing income. The deal also included the sale of Auris Medical Pty Ltd and a cash contribution to Medica's capital. Altamira anticipates a financial gain of about $5.2 million from the transaction, which will be recorded in accordance with International Financial Reporting Standards. The unaudited pro forma financial information reflecting the transaction has been filed with the U.S. Securities and Exchange Commission.
据2024年1月19日报道，百慕大注册公司Altamira Therapeutics Ltd. 已成功完成其Bentrio业务的部分分割，将其子公司Altamira Medica AG的51％股份出售给了一位瑞士私募股权投资者。该交易于2023年11月21日完成，是阿尔塔米拉战略调整的一部分，旨在专注于其RNA交付技术。该公司获得了约230万澳元的现金作为多数股权，并保留了Medica49％的权益。此外，阿尔塔米拉有权获得Medica未来许可总收入的25％。该交易还包括出售Auris Medical Pty Ltd和对Medica资本的现金捐款。阿尔塔米拉预计，该交易将带来约520万美元的财务收益，该收益将按照《国际财务报告准则》进行记录。反映该交易的未经审计的预计财务信息已提交给美国证券交易委员会。
据2024年1月19日报道，百慕大注册公司Altamira Therapeutics Ltd. 已成功完成其Bentrio业务的部分分割，将其子公司Altamira Medica AG的51％股份出售给了一位瑞士私募股权投资者。该交易于2023年11月21日完成，是阿尔塔米拉战略调整的一部分，旨在专注于其RNA交付技术。该公司获得了约230万澳元的现金作为多数股权，并保留了Medica49％的权益。此外，阿尔塔米拉有权获得Medica未来许可总收入的25％。该交易还包括出售Auris Medical Pty Ltd和对Medica资本的现金捐款。阿尔塔米拉预计，该交易将带来约520万美元的财务收益，该收益将按照《国际财务报告准则》进行记录。反映该交易的未经审计的预计财务信息已提交给美国证券交易委员会。
有用
没用